The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description

Louise M. Paterson; Remy S.A. Flechais; Anna Murphy; Laurence J. Reed; Sanja Abbott; Venkataramana Boyapati; Rebecca Elliott; David Erritzoe; Karen D. Ersche; Yetunde Faluyi; Luca Faravelli; Emilio Fernandez-Egea; Nicola J. Kalk; Shankar S. Kuchibatla; John McGonigle; Antonio Metastasio; Inge Mick; Liam Nestor; Csaba Orban; Filippo Passetti; Eugenii A. Rabiner; Dana G. Smith; John Suckling; Roger Tait; Eleanor M. Taylor; Adam D. Waldman; Trevor W. Robbins; Jf William Deakin; David J. Nutt; Anne R. Lingford-Hughes

doi:10.1177/0269881115596155

The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description

Louise M. Paterson, Remy S.A. Flechais, Anna Murphy, Laurence J. Reed, Sanja Abbott, Venkataramana Boyapati, Rebecca Elliott, David Erritzoe, Karen D. Ersche, Yetunde Faluyi, Luca Faravelli, Emilio Fernandez-Egea, Nicola J. Kalk, Shankar S. Kuchibatla, John McGonigle, Antonio Metastasio, Inge Mick, Liam Nestor, Csaba Orban, Filippo PassettiEugenii A. Rabiner, Dana G. Smith, John Suckling, Roger Tait, Eleanor M. Taylor, Adam D. Waldman, Trevor W. Robbins, Jf William Deakin, David J. Nutt^*, Anne R. Lingford-Hughes

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

29 Citations (SciVal)

Original language	English
Pages (from-to)	943-960
Number of pages	18
Journal	Journal of Psychopharmacology
Volume	29
Issue number	9
DOIs	https://doi.org/10.1177/0269881115596155
Publication status	Published (VoR) - 23 Sept 2015

Funding

ICCAM platform collaborators: David Nutt, Anne Lingford-Hughes, Louise Paterson, John McGonigle, Remy Flechais, Csaba Orban, JF William Deakin, Rebecca Elliott, Anna Murphy, Eleanor Taylor, Trevor Robbins, Karen Ersche, John Suckling, Dana Smith, Laurence Reed, Filippo Passetti, Luca Faravelli, David Erritzoe, Inge Mick, Nicola Kalk, Adam Waldman, Liam Nestor, Shankar Kuchibatla, Venkataramana Boyapati, Antonio Metastasio, Yetunde Faluyi, Emilio Fernandez-Egea, Sanja Abbott, Barbara Sahakian, Valerie Voon, Ilan Rabiner. The research was carried out at the NIHR/Wellcome Trust Imperial Clinical Research Facility, the NIHR/Wellcome Trust Cambridge Research Facility and Clinical Trials Unit at Salford Royal NHS Foundation Trust, and is supported by the North West London, Eastern and Greater Manchester NIHR Clinical Research Networks. The views expressed are those of the author(s) and not necessarily those of the Medical Research Council, the NHS, the NIHR or the Department of Health. The authors wish to thank research assistants Claire Whitelock, Heather Agyepong, Rania Christoforou and Natalie Cuzen for their help with data collection, Dr Sharon Morein-Zamir for her help with data extraction from reinforced GoNogo task, MR physicist Rex Newbould and MR technician, Jonathan Howard for their assistance with MR acquisition and task set-up. The authors also wish to thank their recruitment partners; Imperial College Healthcare NHS Trust, Central and North West London NHS Trust, Camden and Islington NHS Trust, Cambridge University Hospitals NHS Foundation Trust, Norfolk and Suffolk NHS Foundation Trust, Cambridge and Peterborough NHS Foundation Trust, South Staffordshire and Shropshire NHS Foundation Trust, Manchester Mental Health NHS and Social Care Trust, Greater Manchester West NHS Foundation Trust, Pennine Care NHS Foundation Trust, Salford Royal NHS Foundation Trust, Addaction, Foundation 66 and CRI (Crime Reduction Initiative). The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This article presents independent research funded by the MRC as part of their addiction initiative (grant number G1000018). GSK kindly funded the functional and structural MRI scans that took place at Imperial College and provided the GSK598809 and vofopitant medication. JF William Deakin currently advises or carries out research funded by Autifony, Sunovion, Lundbeck, AstraZeneca and Servier. All payment is to the University of Manchester. Anne Lingford-Hughes has received honoraria from Lundbeck and research support from GSK for a PhD studentship. Emilio Fernandez-Egea has done consultancy for Roche and received research funding from Genus Pharmaceuticals.

Keywords

Addiction
dopamine D3 receptor
functional magnetic resonance imaging
neurokinin 1 receptor
μ-opioid receptor

Access to Document

10.1177/0269881115596155

Cite this

Paterson, L. M., Flechais, R. S. A., Murphy, A., Reed, L. J., Abbott, S., Boyapati, V., Elliott, R., Erritzoe, D., Ersche, K. D., Faluyi, Y., Faravelli, L., Fernandez-Egea, E., Kalk, N. J., Kuchibatla, S. S., McGonigle, J., Metastasio, A., Mick, I., Nestor, L., Orban, C., ... Lingford-Hughes, A. R. (2015). The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description. Journal of Psychopharmacology, 29(9), 943-960. https://doi.org/10.1177/0269881115596155

@article{16dc60946a144353ae0a5a2f30ee61ba,

title = "The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description",

keywords = "Addiction, dopamine D3 receptor, functional magnetic resonance imaging, neurokinin 1 receptor, μ-opioid receptor",

author = "Paterson, \{Louise M.\} and Flechais, \{Remy S.A.\} and Anna Murphy and Reed, \{Laurence J.\} and Sanja Abbott and Venkataramana Boyapati and Rebecca Elliott and David Erritzoe and Ersche, \{Karen D.\} and Yetunde Faluyi and Luca Faravelli and Emilio Fernandez-Egea and Kalk, \{Nicola J.\} and Kuchibatla, \{Shankar S.\} and John McGonigle and Antonio Metastasio and Inge Mick and Liam Nestor and Csaba Orban and Filippo Passetti and Rabiner, \{Eugenii A.\} and Smith, \{Dana G.\} and John Suckling and Roger Tait and Taylor, \{Eleanor M.\} and Waldman, \{Adam D.\} and Robbins, \{Trevor W.\} and Deakin, \{Jf William\} and Nutt, \{David J.\} and Lingford-Hughes, \{Anne R.\}",

note = "Funding Information: ICCAM platform collaborators: David Nutt, Anne Lingford-Hughes, Louise Paterson, John McGonigle, Remy Flechais, Csaba Orban, JF William Deakin, Rebecca Elliott, Anna Murphy, Eleanor Taylor, Trevor Robbins, Karen Ersche, John Suckling, Dana Smith, Laurence Reed, Filippo Passetti, Luca Faravelli, David Erritzoe, Inge Mick, Nicola Kalk, Adam Waldman, Liam Nestor, Shankar Kuchibatla, Venkataramana Boyapati, Antonio Metastasio, Yetunde Faluyi, Emilio Fernandez-Egea, Sanja Abbott, Barbara Sahakian, Valerie Voon, Ilan Rabiner. The research was carried out at the NIHR/Wellcome Trust Imperial Clinical Research Facility, the NIHR/Wellcome Trust Cambridge Research Facility and Clinical Trials Unit at Salford Royal NHS Foundation Trust, and is supported by the North West London, Eastern and Greater Manchester NIHR Clinical Research Networks. The views expressed are those of the author(s) and not necessarily those of the Medical Research Council, the NHS, the NIHR or the Department of Health. The authors wish to thank research assistants Claire Whitelock, Heather Agyepong, Rania Christoforou and Natalie Cuzen for their help with data collection, Dr Sharon Morein-Zamir for her help with data extraction from reinforced GoNogo task, MR physicist Rex Newbould and MR technician, Jonathan Howard for their assistance with MR acquisition and task set-up. The authors also wish to thank their recruitment partners; Imperial College Healthcare NHS Trust, Central and North West London NHS Trust, Camden and Islington NHS Trust, Cambridge University Hospitals NHS Foundation Trust, Norfolk and Suffolk NHS Foundation Trust, Cambridge and Peterborough NHS Foundation Trust, South Staffordshire and Shropshire NHS Foundation Trust, Manchester Mental Health NHS and Social Care Trust, Greater Manchester West NHS Foundation Trust, Pennine Care NHS Foundation Trust, Salford Royal NHS Foundation Trust, Addaction, Foundation 66 and CRI (Crime Reduction Initiative). Funding Information: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This article presents independent research funded by the MRC as part of their addiction initiative (grant number G1000018). GSK kindly funded the functional and structural MRI scans that took place at Imperial College and provided the GSK598809 and vofopitant medication. Funding Information: JF William Deakin currently advises or carries out research funded by Autifony, Sunovion, Lundbeck, AstraZeneca and Servier. All payment is to the University of Manchester. Funding Information: Anne Lingford-Hughes has received honoraria from Lundbeck and research support from GSK for a PhD studentship. Funding Information: Emilio Fernandez-Egea has done consultancy for Roche and received research funding from Genus Pharmaceuticals. Publisher Copyright: {\textcopyright} The Author(s) 2015.",

year = "2015",

month = sep,

day = "23",

doi = "10.1177/0269881115596155",

language = "English",

volume = "29",

pages = "943--960",

journal = "Journal of Psychopharmacology",

issn = "0269-8811",

publisher = "SAGE Publications",

number = "9",

}

Paterson, LM, Flechais, RSA, Murphy, A, Reed, LJ, Abbott, S, Boyapati, V, Elliott, R, Erritzoe, D, Ersche, KD, Faluyi, Y, Faravelli, L, Fernandez-Egea, E, Kalk, NJ, Kuchibatla, SS, McGonigle, J, Metastasio, A, Mick, I, Nestor, L, Orban, C, Passetti, F, Rabiner, EA, Smith, DG, Suckling, J, Tait, R, Taylor, EM, Waldman, AD, Robbins, TW, Deakin, JW, Nutt, DJ & Lingford-Hughes, AR 2015, 'The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description', Journal of Psychopharmacology, vol. 29, no. 9, pp. 943-960. https://doi.org/10.1177/0269881115596155

The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description. / Paterson, Louise M.; Flechais, Remy S.A.; Murphy, Anna et al.
In: Journal of Psychopharmacology, Vol. 29, No. 9, 23.09.2015, p. 943-960.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - The Imperial College Cambridge Manchester (ICCAM) platform study

T2 - An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description

AU - Paterson, Louise M.

AU - Flechais, Remy S.A.

AU - Murphy, Anna

AU - Reed, Laurence J.

AU - Abbott, Sanja

AU - Boyapati, Venkataramana

AU - Elliott, Rebecca

AU - Erritzoe, David

AU - Ersche, Karen D.

AU - Faluyi, Yetunde

AU - Faravelli, Luca

AU - Fernandez-Egea, Emilio

AU - Kalk, Nicola J.

AU - Kuchibatla, Shankar S.

AU - McGonigle, John

AU - Metastasio, Antonio

AU - Mick, Inge

AU - Nestor, Liam

AU - Orban, Csaba

AU - Passetti, Filippo

AU - Rabiner, Eugenii A.

AU - Smith, Dana G.

AU - Suckling, John

AU - Tait, Roger

AU - Taylor, Eleanor M.

AU - Waldman, Adam D.

AU - Robbins, Trevor W.

AU - Deakin, Jf William

AU - Nutt, David J.

AU - Lingford-Hughes, Anne R.

N1 - Funding Information: ICCAM platform collaborators: David Nutt, Anne Lingford-Hughes, Louise Paterson, John McGonigle, Remy Flechais, Csaba Orban, JF William Deakin, Rebecca Elliott, Anna Murphy, Eleanor Taylor, Trevor Robbins, Karen Ersche, John Suckling, Dana Smith, Laurence Reed, Filippo Passetti, Luca Faravelli, David Erritzoe, Inge Mick, Nicola Kalk, Adam Waldman, Liam Nestor, Shankar Kuchibatla, Venkataramana Boyapati, Antonio Metastasio, Yetunde Faluyi, Emilio Fernandez-Egea, Sanja Abbott, Barbara Sahakian, Valerie Voon, Ilan Rabiner. The research was carried out at the NIHR/Wellcome Trust Imperial Clinical Research Facility, the NIHR/Wellcome Trust Cambridge Research Facility and Clinical Trials Unit at Salford Royal NHS Foundation Trust, and is supported by the North West London, Eastern and Greater Manchester NIHR Clinical Research Networks. The views expressed are those of the author(s) and not necessarily those of the Medical Research Council, the NHS, the NIHR or the Department of Health. The authors wish to thank research assistants Claire Whitelock, Heather Agyepong, Rania Christoforou and Natalie Cuzen for their help with data collection, Dr Sharon Morein-Zamir for her help with data extraction from reinforced GoNogo task, MR physicist Rex Newbould and MR technician, Jonathan Howard for their assistance with MR acquisition and task set-up. The authors also wish to thank their recruitment partners; Imperial College Healthcare NHS Trust, Central and North West London NHS Trust, Camden and Islington NHS Trust, Cambridge University Hospitals NHS Foundation Trust, Norfolk and Suffolk NHS Foundation Trust, Cambridge and Peterborough NHS Foundation Trust, South Staffordshire and Shropshire NHS Foundation Trust, Manchester Mental Health NHS and Social Care Trust, Greater Manchester West NHS Foundation Trust, Pennine Care NHS Foundation Trust, Salford Royal NHS Foundation Trust, Addaction, Foundation 66 and CRI (Crime Reduction Initiative). Funding Information: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This article presents independent research funded by the MRC as part of their addiction initiative (grant number G1000018). GSK kindly funded the functional and structural MRI scans that took place at Imperial College and provided the GSK598809 and vofopitant medication. Funding Information: JF William Deakin currently advises or carries out research funded by Autifony, Sunovion, Lundbeck, AstraZeneca and Servier. All payment is to the University of Manchester. Funding Information: Anne Lingford-Hughes has received honoraria from Lundbeck and research support from GSK for a PhD studentship. Funding Information: Emilio Fernandez-Egea has done consultancy for Roche and received research funding from Genus Pharmaceuticals. Publisher Copyright: © The Author(s) 2015.

PY - 2015/9/23

Y1 - 2015/9/23

KW - Addiction

KW - dopamine D3 receptor

KW - functional magnetic resonance imaging

KW - neurokinin 1 receptor

KW - μ-opioid receptor

UR - https://www.scopus.com/pages/publications/84942093522

UR - https://www.scopus.com/inward/citedby.url?scp=84942093522&partnerID=8YFLogxK

U2 - 10.1177/0269881115596155

DO - 10.1177/0269881115596155

M3 - Article

C2 - 26246443

AN - SCOPUS:84942093522

SN - 0269-8811

VL - 29

SP - 943

EP - 960

JO - Journal of Psychopharmacology

JF - Journal of Psychopharmacology

IS - 9

ER -

The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description

Funding

Keywords

Access to Document

Other files and links

Fingerprint

Cite this